Full history for every metric is available with a Kvantra account

Stock profile
Exelixis, Inc. logo

Exelixis, Inc. (EXEL)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
19.4
History
P/E NTM
17.4
Market cap
16.25B
Currency USD
KvantraRankAbout79
IValue63
IIQuality99
IIIMomentum76
Current price
64.63 USD-1.82%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m9881,4351,6111,8302,1692,3202,4972,557
Operating profit$m8721,003
Net profit$m1122311822085217838851,041
EPS reported$2.783.34
Operating cashflow per share$3.264.75
Capex per share$0.150.09
FCF per share$3.114.67
Free cash flow$m8441,152
Net debt$m-886-730
Book value equity$m2,1611,834
Book value per share$7.677.17
Number of sharesm281.86255.75
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx15.6819.35
P/B LTMx5.488.86
P/S LTMx5.106.51
P/FCF LTMx14.0214.10
EV/EBITDA LTMx12.5014.41
EV/Sales LTMx4.976.21
Earnings Yield LTM%6.38%5.17%
FCF Yield%7.13%7.09%
Quality
ROE%36.21%45.54%
ROIC%29.74%39.65%
Operating margin%37.59%40.19%
Gross margin%96.39%96.26%
FCF/Sales%36.39%46.14%
Growth and momentum
EPS Growth YoY%+57.95%+40.93%
Sales Growth YoY%+6.98%+9.12%
Net Income Growth YoY%+50.13%+30.57%
FCF Growth%+33.22%+54.79%
Operating Profit Growth%+44.26%+25.40%
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx4.887.10
Net Debt/EBITDAx-0.34-0.13
EBIT/Net interestx--
Net debt/market cap%-7.49%-4.49%
Net debt/Equityx-0.41-0.40
Gross debt/equityx0.080.09

ETFs that hold Exelixis

FundTickerPosition#Weight
State Street SPDR S&P Biotech ETFXBI21.79%
Schwab Fundamental U.S. Small Company Index ETFFNDA70.35%
Invesco S&P MidCap Quality ETFXMHQ43.76%
First Trust NYSE Arca Biotechnology Index FundFBT93.76%
Fidelity Small-Mid Multifactor ETFFSMD80.36%
Janus Henderson Small/Mid Cap Growth Alpha ETFJSMD71.89%
TD Q U.S. Small-Mid-Cap Equity ETFTQSM.TO51.23%
First Trust Mid Cap Growth AlphaDEX FundFNY60.88%
JPMorgan Diversified Return U.S. Mid Cap Equity ETFJPME60.47%
JPMorgan Diversified Return U.S. Equity ETFJPUS10.47%

Funds with Exelixis among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price64.63 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Exelixis, Inc. (EXEL)

EXEL · NASDAQ · Healthcare
64.63 USD-1.82%
Sign up to track this stock
Benchmarks
KvantraRank79
Market cap16.25B
P/E NTM17.4
P/E TTM19.4
KvantraRank?79 / 100
Value
63
Quality
99
Momentum
76
Financialsin USD
20242025TTM2026E
ETFs that hold Exelixis
FundTickerPosition#Weight
State Street SPDR S&P Biotech ETFXBI21.79%
Schwab Fundamental U.S. Small Company Index ETFFNDA70.35%
Invesco S&P MidCap Quality ETFXMHQ43.76%
First Trust NYSE Arca Biotechnology Index FundFBT93.76%
Fidelity Small-Mid Multifactor ETFFSMD80.36%
Janus Henderson Small/Mid Cap Growth Alpha ETFJSMD71.89%
TD Q U.S. Small-Mid-Cap Equity ETFTQSM.TO51.23%
First Trust Mid Cap Growth AlphaDEX FundFNY60.88%
JPMorgan Diversified Return U.S. Mid Cap Equity ETFJPME60.47%
JPMorgan Diversified Return U.S. Equity ETFJPUS10.47%

Funds with Exelixis among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current64.63 USD
Upside
Price consensus
Last year average price target
Current price64.63 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free